Jing Jing Wang

Flinders University

GPO Box 2100

Adelaide S.A. 5001, 5063

Australia

SCHOLARLY PAPERS

3

DOWNLOADS

250

TOTAL CITATIONS

2

Scholarly Papers (3)

1.

Heparin- and Vaccine-Independent Anti-Platelet Factor 4 Immunothrombosis

Number of pages: 31 Posted: 26 Jul 2023
Universitätsmedizin Greifswald, Werfen, Universitätsmedizin Greifswald, Werfen, Werfen, Werfen, Universitätsmedizin Greifswald, Werfen, Werfen, Werfen, Werfen, Flinders University, Flinders University, Cardioangiology Center Bethanien Hospital - CCB Coagulation Center and CCB Coagulation Research Center, Heinrich Heine University Dusseldorf - Institute for Transplant Diagnostics and Cell Therapeutics, University of Lausanne - Haematology Service, University of Hamburg - Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, Medical University of Innsbruck, Oncology Institute of Southern Switzerland - Clinic of Haematology, Ludwig Maximilian University of Munich (LMU) - Dr. von Hauner Children's Hospital, Charité - Universitätsmedizin Berlin - Klinik und Hochschulambulanz für Neurologie, Carl von Ossietzky University of Oldenburg, Rostock University Medical Centre, McMaster University and Universitätsmedizin Greifswald - Institut für Immunologie und Transfusionsmedizin
Downloads 112 (530,653)
Citation 2

Abstract:

Loading...

VITT, HIT, TTS, platelet factor 4, vaccination, COVID-19, thrombosis

2.

Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 th Dose Booster

Number of pages: 43 Posted: 29 Jun 2023
University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne - Departments of Medicine and Infectious Diseases at the Doherty Institute, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne, Flinders University, University of Melbourne, University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Centre for Epidemiology and Biostatistics, University of Melbourne, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, SingHealth Duke-NUS Global Health Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), Flinders University, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, Monash University - Monash Institute of Pharmaceutical Sciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Monash University - Monash Institute of Pharmaceutical Sciences and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 108 (545,094)

Abstract:

Loading...

SARS-CoV-2, vaccine, receptor binding domain, recombinant protein, mRNA, beta variant, phase I trial.

3.

B Cell Signatures and Antibody Imprinting Define HCV Reinfection Outcome

Number of pages: 56 Posted: 18 Apr 2023
University of Copenhagen - Department of Immunology and Microbiology, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, Burnet Institute, Flinders University, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, University of Copenhagen - Department of Immunology and Microbiology, University of New South Wales (UNSW) - Kirby Institute, Flinders University, University of New South Wales (UNSW) - Kirby Institute, University of New South Wales (UNSW) - Kirby Institute, Burnet Institute, University of New South Wales (UNSW) - Kirby Institute and University of New South Wales (UNSW) - Kirby Institute
Downloads 30 (1,035,555)

Abstract:

Loading...

Hepatitis C virus, neutralising antibodies, immune imprinting, viral persistence, memory B cells